OneSource Specialty Pharma Ltd
Incorporated in 2007, OneSource Specialty Pharma Ltd is in the research, development, manufacture and commercialisation of bio
logical drug products in various injectable formats. It also offers end-to-end CDMO
services across all phases of pre-clinical
and clinical development and commercial
supply of biologics[1]
- Market Cap ₹ 18,738 Cr.
- Current Price ₹ 1,635
- High / Low ₹ 2,250 / 1,163
- Stock P/E 136
- Book Value ₹ 516
- Dividend Yield 0.00 %
- ROCE 5.52 %
- ROE 3.34 %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Stock is trading at 3.17 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -17.7% over last 3 years.
- Promoters have pledged or encumbered 26.0% of their holding.
- Debtor days have increased from 86.2 to 105 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 21 | 128 | 39 | 172 | 1,445 | 1,522 | |
| 93 | 132 | 199 | 254 | 978 | 1,002 | |
| Operating Profit | -71 | -4 | -161 | -82 | 467 | 519 |
| OPM % | -334% | -3% | -415% | -48% | 32% | 34% |
| 1 | -128 | -526 | -143 | -94 | -86 | |
| Interest | 16 | 46 | 48 | 89 | 166 | 141 |
| Depreciation | 34 | 53 | 66 | 76 | 274 | 275 |
| Profit before tax | -121 | -231 | -800 | -391 | -68 | 18 |
| Tax % | 0% | -0% | 0% | 0% | -73% | |
| -121 | -231 | -800 | -391 | -18 | 40 | |
| EPS in Rs | -1.57 | 3.49 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 124% |
| TTM: | 101% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| TTM: | 202% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -18% |
| Last Year: | 3% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 3 | 4 | 4 | 11 | 11 |
| Reserves | 774 | 1,009 | 781 | 392 | 5,869 | 5,893 |
| 386 | 1,182 | 864 | 571 | 772 | 1,295 | |
| 96 | 248 | 365 | 459 | 1,005 | 814 | |
| Total Liabilities | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
| 633 | 1,231 | 1,361 | 863 | 6,118 | 6,286 | |
| CWIP | 431 | 490 | 334 | 188 | 218 | 173 |
| Investments | 0 | 0 | 4 | 20 | 16 | 20 |
| 195 | 722 | 314 | 356 | 1,305 | 1,535 | |
| Total Assets | 1,258 | 2,442 | 2,015 | 1,426 | 7,657 | 8,013 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -118 | -416 | -163 | -107 | -68 | |
| -207 | -692 | -68 | 511 | -201 | |
| 381 | 1,162 | 118 | -391 | 412 | |
| Net Cash Flow | 56 | 54 | -112 | 13 | 143 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | 38 | 67 | 36 | 117 | 105 |
| Inventory Days | 87 | 615 | 258 | 222 | |
| Days Payable | 762 | 420 | 163 | 147 | |
| Cash Conversion Cycle | -637 | 67 | 232 | 212 | 180 |
| Working Capital Days | -2,392 | -1,331 | -6,745 | -877 | -58 |
| ROCE % | -3% | -12% | -12% | 6% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
2d - In reference to our intimation dated 09.12.2025, where the number of shares allotted was intimated as 11,45,62,136 instead of 23,000 equity shares of Re. 1/- …
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
9 Dec - Allotment of 11,45,62,136 Equity Shares of RE.1/- each under Onesource ESOP 2021
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
18 Nov - Transcript of the earnings call for the quarter and half year ended September 30, 2025 held on November 12, 2025 i.e. after the Board Meeting …
-
Update On Non-Participation Of The Representatives Of The Company In The Jefferies Conference
18 Nov - Company will not participate in Jefferies Global Healthcare Conference Nov 18–20, 2025.
-
General Updates
13 Nov - OneSource to attend Jefferies Global Healthcare Conference in London, Nov 18–20, 2025; no UPSI shared.
Annual reports
Concalls
-
Nov 2025Transcript PPT REC
-
Sep 2025TranscriptAI SummaryPPT
-
Aug 2025Transcript PPT REC
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
Business Overview:[1]
OSSPL is a subsidiary of Strides Pharma
Ltd. The company is a Contract Development
and Manufacturing Organisation that caters
to several biopharma and biotech companies.
It covers the entire CDMO value chain, from clinical development to technology transfer
to commercial manufacture and regulatory assistance.